Publications by authors named "Jim Cavet"

Claim this Profile
L
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
Lydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, Kent Fung, Julia Taylor, Jim Cavet

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management of Castleman disease.
Oliver C Lomas, Matthew Streetly, Guy Pratt, Jim Cavet, Daniel Royston

Br J Haematol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab.
Sally Thirkettle, Joanne Russell, Sarah Wilson, Tasneem Ganijee, Samar Kulkarni, Jim Cavet

Ann Clin Biochem· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
Sam H Ahmedzai, John A Snowden, Andrew John Ashcroft, David Allan Cairns, Cathy Williams, Jim Cavet

J Clin Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Gordon Cook, Kara-Louise Royle, Sheila O'Connor, David A Cairns, A John Ashcroft, Jim Cavet

Br J Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Michele Cavo, Evangelos Terpos, Joan Bargay, Hermann Einsele, Jim Cavet

Expert Rev Hematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Gordon Cook, A John Ashcroft, David A Cairns, Cathy D Williams, Julia M Brown, Jim Cavet

Lancet Haematol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Christopher Parrish, Curly T C M Morris, Cathy D Williams, David A Cairns, Jamie Cavenagh, Jim Cavet

Biol Blood Marrow Transplant· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.
Christopher Parrish, Amin Rahemtulla, Jim Cavet, Rachel M Pearce, Keiren Kirkland

Biol Blood Marrow Transplant· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Gordon Cook, Cathy Williams, Julia M Brown, David A Cairns, Jamie Cavenagh, Jim Cavet

Lancet Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for mortality with fungal blood stream infections in patients with hematological and non-hematological malignancies.
Zena Salih, Jim Cavet, Mike Dennis, Tim Somervaille, Adrian Bloor

South Asian J Cancer· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.
Gordon Cook, Effie Liakopoulou, Rachel Pearce, Jim Cavet, Gareth J Morgan

Biol Blood Marrow Transplant· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-transplantation after bortezomib-based therapy.
Curly Morris, Gordon Cook, Matthew Streetly, Paul Kettle, Mary Drake, Jim Cavet

Br J Haematol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding distress and distressing experiences in patients living with multiple myeloma: an exploratory study.
Barbara Potrata, Jim Cavet, Susan Blair, Tracy Howe, Alex Molassiotis

Psychooncology· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome.
Eleni Tholouli, Simon Watt, Guy S Lucas, John Burthem, John A Liu Yin, Jim Cavet

Blood· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis